Evaluation of Intermittent Triple Therapies in Real Life
Recruiting now
Conditions studied: HIV Infections
In brief
The strategy of intermittent triple therapy for people living with HIV was validated in France following the randomized clinical trial QUATUOR. There is little data in real life, as shown in the meta-analysis of Parienti JJ et al. Currently this strategy is proposed by some teams in France, but is not recommended internationally. The research hypothesis is that intermittent treatment is an effective and safe option in a therapeutic lightening strategy in people living with HIV People living with HIV adults followed in Strasbourg who have benefited from intermittent treatment The expected results will consist of an improvement in knowledge on the efficacy and tolerance of this therapeutic strategy.
Key facts
- Study ID
- NCT06578702
- Run by
- University Hospital, Strasbourg, France
- People needed
- 200
- Starts
- 2024-02-21
- Expected to finish
- 2025-02-21
- Last updated by the study team
- 2024-08-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult subject (≥ 18 years old)
- Living with HIV monitored at the Trait d'Union/Infectious Diseases department in Strasbourg
- Having benefited from intermittent triple therapy between 01/01/2017 and 31/01/2024
You may not qualify if…
- Subject (and/or their legal representative if applicable) having expressed their opposition to the reuse of their data for scientific research purposes.
Where it is running
- Service Le Trait d'Union - CHU de Strasbourg - France — Strasbourg, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.